good estimate of measured GFR. 7) The current guidelines of CKD classify chronic kidney disease by eGFR, one of which is calculated by the Modification of Diet in Renal Disease study (MDRD) formula. 8) Moreover, eGFR is a strong predictor of cardiovascular mortality. 2) Despite of these facts, it is undetermined whether eGFR predicts postoperative outcomes after cardiac surgery; it is also unknown whether eGFR is a better index than serum creatinine.
The purpose of this study was to analyze whether the eGFR classification based on the current guideline is associated with early and late outcomes of mitral valve surgery. Furthermore, this study examined whether eGFR is an independent predictor of early and long-term morbidity and mortality.
Patients and Methods
Between January 2004 and December 2011, 343 patients underwent mitral valve procedures for mitral regurgitation (MR) at our institute. Of these patients, redo operations and concomitant procedures on aortic valve or thoracic aorta were excluded; 210 patients were included in the study. All data were obtained retrospectively from the medical records. The Institutional Review Board approved this study, and patient consent was waived due to the retrospective nature of data collection. According to a recommendation from the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF KDOQI™) clinical practice guidelines, eGFR was calculated by the MDRD Study equation. 8) Based on eGFR, patients were separated into 3 subgroups: Group A (eGFR ≥60 ml/min/1.73 m 2 ), Group B (eGFR, 59-30 ml/min/1.73 m 2 ), and Group C (eGFR <30 ml/ min/1.73 m 2 ). These subgroups correspond to CKD Stage 1-2, Stage 3 and Stage 4-5, respectively. Patients who were on preoperative hemodialysis received hemodialysis a day before surgery, which was resumed on postoperative day 1 or 2, depending on patients' arterial blood gas and fluid status. Renal replacement therapy (RRT) was applied either in continuous or intermittent manner for patients who were not on preoperative hemodialysis and presented postoperative acute renal failure despite optimal hemodynamic management. Our criteria for initiating RRT was as follows: Oliguria (<0.5 ml/kg/ hour) and fluid overload as evident by chest X-ray; decrease in eGFR <15 ml/min/1.73 m 2 ; symptoms or signs of uremia; and intractable hyperkalemia or metabolic acidosis. 9) All procedures were performed using standard cardiopulmonary bypass with bicaval and aortic cannulation under tepid temperature. A higher mean perfusion pressure (which was usually 80 mmHg) was maintained on bypass. For renoprotective purpose, human atrial natriuretic polypeptide (Carperitide) is administered continuously in most cases, irrespective of preoperative renal function. 10) If excessive hemodilution was observed, intraoperative modified ultrafiltration was liberally done. 11) Choice of repair procedure or replacement was decided based on surgeon's preference. Generally, mitral ring annuloplasty was performed for Carpentier Type I or Type IIIb (functional) MR, and chordal replacement or quadrangular resection was performed for Type II MR. An annuloplasty ring or band was used in all repair cases.
Patients were followed-up by the clinic at our hospital, or using telephone interview. Follow-up in this patient series was 100%. The mean follow-up period was 3.36 ± 2.10 years.
Statistical analyses were performed using JMP ® 10 (SAS Institute Inc., Cary, North Carolina, USA). Normally distributed continuous data were expressed as means ± SD. Univariate analyses were performed for all relevant categorical variables using Fisher's exact test, χ 2 analysis, and t tests or Mann-Whitney U test for continuous variables. Logistic regression was used to examine independent predictors of morbidity or mortality. Because of the strong interaction between eGFR and serum creatinine, these indices were excluded in the 2 separate analyses. Kaplan-Meier analysis was performed to depict all-cause or event-free survivals, using Log-rank tests for statistical analysis. The differences were considered statistically significant at p <0.05.
Results
The clinical characteristics of patients are shown in Table 1 . A total of 93 males (44%) and 117 females with a mean age of 69.6 ± 11.5 years (range: 25-90 years) were included in the study. Etiology was degenerative in 146 patients (70%), functional in 54 (25%), and rheumatic in 10 (5%). The mean serum creatinine of overall patients was 1.05 ± 0.80 mg/dl, and the mean eGFR was 56.6 ± 19.9 ml/min/1.73 m 2 . Based on eGFR, patients were separated into three subgroups: Group A (eGFR ≥60 ml/ min/1.73 m 2 , n = 102), Group B (eGFR, 59-30 ml/min/ 1.73 m 2 , n = 92), and Group C (eGFR <30 ml/min/1.73 m 2 , n = 16). Mean serum creatinine and eGFR of each group were as follows: Group A: 0.73 ± 0.13 mg/dl and 73.2 ± 11.2 ml/min/1.73 m 2 ; Group B: 1.09 ± 0.13 mg/dl and 44.8 ± 8.32 ml/min/1.73 m 2 ; and Group C: 2.92 ± 4.01 mg/dl and 19.3 ± 7.91 ml/min/1.73 m 2 (p <0.001). As shown in Table 1 , patients in Group A were younger, Group C patients had more comorbidities than Groups A and B, and prevalence of diabetes and coronary disease significantly increased as eGFR declined. Three patients in Group C were on hemodialysis preoperatively. There was no difference in echocardiographic parameters between the groups.
The operative variables are detailed in Table 1 . There was no difference in ratio of valve repair or replacement (14) 15 (15) 13 (14) 1 (6) 0.862
44 (21) 18 (18) 20 (22) and concomitant procedures between groups. Likewise, there was no difference in operative, cardiopulmonary bypass, or aortic clamp time between groups. There were four operative deaths; however, no differences between groups in this regard. Significant differences were found for the incidences of postoperative renal replacement therapy, respiratory failure, and transfusion. These incidences were significantly higher in Group C compared to the others. Postoperatively, patients in Group C were less likely to be on angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) than those in other groups ( Table 1) .
A mean and median follow-up durations were 40.3 ± 25.2 months and 41 months, respectively. Kaplan-Meier analysis demonstrated that overall survival was 77.2% at 5 years: 80.1%, 76.9%, 62.6% for Groups A, B, and C, respectively. The survival of Group C was worse than that of the other groups, although the difference did not reach statistical significance (Fig. 1A) . Likewise, there was no significant difference in cardiovascular death between groups (Fig. 1B) . In contrast, overall freedom from major adverse cardiovascular events (MACE) was 62.2%, and 80.1%, 76.9%, and 62.6% in Groups A, B, and C, respectively. MACE-free survival significantly decreased as eGFR declined (Fig. 2, p = 0.008) . To determine risk factors of MACE, univariate analysis was performed. Factors that reached statistical significance were as follows: coronary artery disease, left ventricular ejection fraction (LVEF) less than 40%, eGFR less than 60 ml/ min/1.73 m 2 , and serum creatinine greater than 0.9 mg/dl ( Table 2) . Multivariate analysis including eGFR revealed that LVEF <40% (HR: 2.69, 95% CI: 1.17-6.23, p = 0.02) and eGFR <60 ml/min/1.73 m 2 (HR: 1.92, 95% CI: 1.02-3.68, p = 0.044) were independent predictors of MACE ( Table 3) . In contrast, multivariate analysis including serum creatinine showed that only LVEF <40% (HR: 2.80, 95% CI: 1.22-6.47, p = 0.016) was statistically significant; coronary disease (HR: 1.63, 95% CI: 0.81-3.21, p = 0.17) and serum creatinine (HR: 1.77, 95% CI: 0.93-3.44, p = 0.08) were not significant. These findings suggest that eGFR has a stronger correlation with MACE than serum creatinine.
Discussion
It is widely known that renal dysfunction is an important factor for predicting early and long-term morbidity and mortality after cardiac surgery. 3, 12) This finding has been relatively well documented in coronary bypass 4, 5) or aortic valve surgery, 6) although fewer data are available for mitral valve surgery. Garriodo-Olivares and colleagues 13) demonstrated that preoperative non-dialysis dependent renal dysfunction impacts early mortality after mitral valve surgery significantly. Jokinen and colleagues 14) reported that preoperative renal dysfunction is associated with late mortality after mitral valve surgery.
In the present study, we demonstrated that preoperative renal dysfunction, defined based on the classification of the CKD guidelines, is associated with late MACE after mitral valve surgery. It was also shown that eGFR and low LVEF are independent predictors of late MACE.
In most previous studies, renal dysfunction has mainly been defined by serum creatinine, and eGFR has been underutilized despite recommendations of the CKD guidelines. Surprisingly, few data are available that demonstrate that eGFR as a predictor of early and late outcomes after cardiac surgery. Although serum creatinine is an authentic marker of renal function, eGFR is a more comprehensive index and is determined in combination with age, sex, weight, and race. Because age has a strong correlation with long-term morbidity and mortality, the use of eGFR may be superior to serum creatinine alone. Moreover, serum creatinine generation and filtration are affected by various factors, and begins increasing only after significant loss of functioning nephrons and decreases of glomerular filtration. 1, 8) Therefore, it is very likely that eGFR is a more sensitive marker of preoperative renal function than is serum creatinine. In the present a Continuous data presented as mean and standard deviation, and categorical data as number (%). MACE: major adverse cardiovascular event; LVEF: left ventricular ejection fraction; eGFR: estimated glomerular filtration rate; HR: hazard ratio; CI: confidential interval study, we clearly showed that eGFR represents a useful marker to predict late morbidity after mitral valve surgery. Other biomarkers that are used for perioperative renal function. Serum cystatin C is a relatively new marker that indicates the ability of glomerular filtration; a number of studies have demonstrated that serum cystatin C levels correlate well with serum creatinine in post cardiopulmonary bypass acute kidney injury. 15, 16) Spahillary and colleagues conducted a multi-center prospective cohort study and found that preoperative serum cystatin C better forecasted postoperative acute kidney injury than did creatinine. 17) Conversely, the same group failed to demonstrate whether serum cystatin C changed more sensitively than did creatinine in postoperative acute kidney injury. 18) Proteinuria or albuminuria is another marker that reflects structural damage to the glomeruli or kidney tubules. 19) Coca and colleagues reported that preoperative albuminuria was an independent predictor of acute kidney injury and added a prognostic value to eGFR. 20) It is yet to be determined whether these markers are likely to replace creatinine-based eGFR in risk analysis for acute kidney injury and long-term outcomes of cardiac surgery.
Overall survival of our series was 77.2% at 5 years, which is comparable with other series. 21) In contrast to previous reports, we did not find significant differences in early and late survival between three groups, albeit a trend toward the worse long-term survival of patients with eGFR <30 ml/min/1.73 m 2 . This finding implies that our patients with renal dysfunction had acceptable early and late mortality. Interestingly, it has been shown that Japanese patients with renal failure have better clinical outcomes than do patients in western countries. 22) This difference is possibly because of their health insurance system that allows easier access to hemodialysis and more frequent checkups. 22) Therefore, it is possible that postoperative management may have improved outcomes of patients with mild to moderate renal insufficiency. For example, it is well known that blockade of the renin-angiotensin system is the main aim of therapy to slow progression of chronic kidney disease and improve survival. 23) Benedetto and colleagues reported that preoperative ACEI reduced postoperative acute kidney injury almost in half, which suggests a protective effect of ACEI on renal perfusion during cardiopulmonary bypass. 24) In the present study, about 90% of patients were on ACEI and/or ARB postoperatively. It is yet to be determined how medical management affected postoperative survival or MACE. Furthermore, only 3 patients (1.4%) in group C were on preoperative hemodialysis in this series, which may be too small to affect survival.
Mild renal dysfunction is known to be a predictor of early and long-term worse outcomes after cardiac surgery. 25) In the present study, 2 patients in Group A and 4 in Group B had postoperative acute kidney injury and underwent temporary renal replacement therapy. These patients had prolonged bypass time (mean, 192 minutes), and 3 had a LVEF of less than 40%. Thus, it is likely that prolonged low cardiac output adversely affected renal function. To protect renal function, it is paramount to reduce cardiopulmonary bypass time as much as possible. Moreover, Carperitide is known to exert cardio and renoprotective effects even in patients with mild to moderate renal dysfunction. 26) It is intriguing to examine whether perioperative Carperitide improves postoperative outcomes in mitral valve surgery.
It has been well documented that preoperative left ventricular function is associated with worse late outcomes and is not limited to mitral valve cases. In the present study, LVEF was another strong predictor of late MACE, which is consistent with others. 21) It is noteworthy that type of procedure (i.e., valve repair or replacement) and valve choice did not affect short and long-term outcomes. Recent data have supported that there is no difference in postoperative survival of patients with end-stage renal failure irrespective of valve choices. 27 ) Thus, our current strategy for mitral valve disease is to recommend an early operation before ventricular function declines and perform valve repair as much as possible. If valve replacement is needed, we usually opt to use a tissue valve unless the patient declines.
There are several limitations in this study. The retrospective nature is one of the major limitations. Additionally, the sample size was small, which may have lead to a Type II statistical error. The follow-up period was short for some patients. Propensity score matching was not possible because of the small numbers of each group. Patients with very poor renal function might not have been operated due to high EURO score, which may not exclude the possibility of selection bias. Finally baseline etiology of mitral valve disease and concomitant procedures were diverse, which might have affected the short and long-term results.
Conclusion
In conclusion, our series of mitral valve surgery had acceptable perioperative and long-term outcomes, even in patients with renal dysfunction. eGFR is a good index to predict long-term outcome after mitral valve surgery, and should be included with serum creatinine in preoperative patient evaluation. Further studies are warranted to determine the role of preoperative eGFR in pre and postoperative patient management.
